The Treatment and Follow-Up of Anti-LGI1 Limbic Encephalitis.
Changchun, China. In Eur Neurol, Jan 2016
OBJECTIVE: This study aims to retrospectively study clinical characteristics, diagnosis, treatment and follow-up visits in patients with anti-leucine-rich glioma inactivated-1 (LGI1) limbic encephalitis (LE) for prompting the early diagnosis and efficacious treatment of this disease.
Pathologically confirmed autoimmune encephalitis in suspected Creutzfeldt-Jakob disease.
Utrecht, Netherlands. In Neurol Neuroimmunol Neuroinflamm, Dec 2015
Antineuronal antibodies were tested in CSF obtained postmortem by immunohistochemistry on fresh frozen rat brain sections, by Luminex assay for the presence of well-characterized onconeural antibodies, and by cell-based assays for antibodies against NMDAR, GABABR1/2, GABAAR GLUR1/2, LGI1, Caspr2, and DPPX.
[LGI1 ENCEPHALITIS: THE FIRST HUNGARIAN PATIENT].
In Ideggyogy Sz, Aug 2015
In the recent years, it has been increasingly recognised that in a group of limbic encephalitis antibodies are directed against the scaffolding protein LGI1 (Leucine-rich glioma inactivated 1), which is part of the voltage gated potassium channel (VGKC) complex on neural synapses.
Genetic models of focal epilepsies.
Paris, France. In J Neurosci Methods, Jul 2015
In this article, we provide an update on the mutational spectrum of neuronal nicotinic acetylcholine receptor genes (CHRNA4, CHRNB2, CHRNA2) and KCNT1 causing autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), and of LGI1 in autosomal dominant epilepsy with auditory features (ADEAF).